Loading clinical trials...
Loading clinical trials...
Clinical and Basic Investigations Into Phosphomannomutase Deficiency (PMM2-CDG)
Clinical and Basic Investigations into Phosphomannomutase deficiency (PMM2-CDG) This is a natural history (observational) protocol designed to collect clinical and biological information in patients with PMM2-CDG (CDG-Ia).
Subjects enrolled in this natural history study will be thoroughly examined for signs and symptoms of PMM2-CDG. Medical history, physical examination, laboratory testing and imaging studies will be performed during a single consultation. Follow-up will occur every 3- 6 months at a minimum, depending on the standard of care at the investigator's institution as well as the clinical status of the individual patient. All medical procedures are routine. No new therapy is offered as part of this study, and no change in the patients routine therapy is dictated by this protocol. The International Co-Operative Ataxia Rating Scale (ICARS) is to be performed every 3 months as an optional assessment. No randomization will be performed.
Age
All ages
Sex
ALL
Healthy Volunteers
No
Mayo Clinic College of Medicine
Rochester, Minnesota, United States
Children's Hospital of Philadelphia (CHOP)
Philadelphia, Pennsylvania, United States
Seattle Children's Hospital
Seattle, Washington, United States
University Hospital Leuven
Leuven, Belgium, Belgium
General University Hospital in Prague
Prague, Czechia
Necker Enfants-Malades Hospital
Paris, France
University Hospital of Catania
Catania, Italy
Radboud University Nejmegen Medical Center
Nijmegen, Netherlands
Mother and Child Institute (Instytut Matki i Dziecka)
Warsaw, Poland
Centro Hospitalar do Porto
Porto, Portugal
Start Date
January 8, 2018
Primary Completion Date
March 1, 2026
Completion Date
March 1, 2026
Last Updated
November 18, 2025
120
ESTIMATED participants
Lead Sponsor
Glycomine, Inc.
NCT06892288
NCT05549219
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions